MOTS-c research, exercise and safety
MOTS-c is a small peptide made by the body. Its genetic instructions are found in mitochondria, the structures within cells that help supply energy. It has been measured in blood and muscle, and researchers are studying its connections with metabolic stress and physical activity.
Three kinds of evidence need to stay separate: experiments that give MOTS-c to animals, studies that measure the body's own MOTS-c in people, and trials that test it as a treatment. A blood association is not a treatment result, even when both use the same peptide name.
Exercise and muscle research

A 2021 study connected MOTS-c with exercise. Its experiments included natural peptide measurements and administration of MOTS-c to mice. Treated mice showed changes in physical performance, including running capacity, grip strength, and gait. The paper studied animals of different ages.
That provides a reason to investigate muscle biology. It does not show that administering MOTS-c improves endurance or reverses aging in people. Exercise changing a naturally occurring signal and a treatment changing an outcome are separate observations. Neither can stand in for the other without further experiments.
Ordinary movement also involves many signals at once. Naming a peptide associated with exercise does not make it a substitute for that activity, or establish that raising its level reproduces all the effects of exercise. The human treatment question requires its own controlled evidence.
What happens within cells
In cell research published in 2018, metabolic stress caused MOTS-c to move into the nucleus, the compartment containing most of a cell's genetic information. The experiments linked that movement with changes in stress-response genes. These were laboratory observations, not measurements of recovery or health in treated patients.
A 2024 muscle study identified CK2 as a target. CK2 is an enzyme, a protein that helps chemical reactions occur. The work combined direct-binding tests with mouse experiments. It adds detail about how MOTS-c may act in research systems; it does not establish a clinical benefit from a preparation offered to people.
Natural blood levels in kidney disease
The 2024 hemodialysis cohort followed 94 people receiving long-term dialysis. Higher circulating MOTS-c was associated with a combined outcome of death or nonfatal cardiovascular events. Including the measurement improved the study's risk model. Participants were not given MOTS-c as a treatment.
This is biomarker research: a biomarker is a measurable feature that may help describe a biological state. The association cannot determine whether MOTS-c caused harm, reflected serious illness, or formed part of a response to illness. It also supplies no target blood level for people outside that population.
Human safety remains uncertain
FDA's July 2026 review of MOTS-c found important gaps in human safety information and in basic animal toxicity testing. It raised concerns about immune reactions, peptide clumping, impurities, and characterization of the ingredient. Those are assessed risks and missing information, rather than measured frequencies of side effects in treated people.
A registered MOTS-c trial describes a study in adults with prediabetes and overweight or obesity. The record available to this site has no results. Registration makes a research plan visible; it cannot answer the safety or effectiveness questions the study is intended to test.
The body's ability to make MOTS-c does not establish the safety of administering extra peptide. Natural production, a manufactured preparation, and the amount reaching a tissue are different issues. Reliable human treatment rates for adverse effects cannot be inferred from the mouse performance studies or the dialysis cohort.
FDA status and the HHS draft
MOTS-c is not an FDA-approved medicine. On FDA's page current as of April 22, 2026, it appears among nominated but withdrawn substances, rather than in the current Category 2 table. Withdrawal did not confer clearance, and FDA provides no individual withdrawal date there.
In an October 30, 2026 draft policy, HHS described its intention not to take enforcement action against state-licensed pharmacies and licensed physicians compounding MOTS-c for an individual patient's prescription when the specified conditions are met. The policy is nonbinding, gives no FDA approval, and leaves MOTS-c outside FDA's 503A bulks list.
The draft covers single-ingredient preparations meeting its conditions, not blends or 503B outsourcing facilities. These policy distinctions do not resolve the missing human treatment evidence. The comparison page explains why a regulatory development and a new clinical result answer different questions.